HPLC, UHPLC
Four-Channel HPLC Increases Clinical Throughput Capabilities with Class I Medical Device Listing
Jul 27 2015
Clinical laboratories requiring high-throughput separations for their LC-MS assays now have access to a new four-channel, high-performance liquid chromatography (HPLC) system designed to increase the productivity and efficiency of clinical sample separations, while freeing valuable bench space.
Listed with the FDA as a Class I medical device for general clinical use, the Thermo Scientific Prelude LX-4 MD HPLC quadruples the productivity of a single-channel HPLC using four parallel channels that deliver up to four separations in a single instrument, streamlining LC-MS workflows and reducing mass spectrometer idle time. The four channels can run identical or different LC-MS assays simultaneously, which provides flexibility for varying clinical separations and maximises mass spectrometer utilisation.
"We are strongly committed to bringing the advantages of LC-MS to the clinical market,” said Bradley Hart, director of market development for Thermo Fisher Scientific. “The Prelude LX-4 MD is one of the first products within a broader initiative to make sample separations and mass spectrometry more useful and accessible to the clinician.”
The Prelude LX-4 MD is the newest addition to the family of Thermo Scientific chromatography and mass spectrometry instruments and software for the clinical lab, which includes the Thermo Scientific Endura MD triple quadrupole mass spectrometer, Prelude MD HPLC and ClinQuan MD software, designed for clinical analyses of patient samples.
More information on the Prelude LX-4 MD HPLC can be found here.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Jan 20 2025 Amsterdam, Netherlands
Feb 03 2025 Dubai, UAE
Feb 05 2025 Guangzhou, China
Mar 01 2025 Boston, MA, USA
Mar 04 2025 Berlin, Germany